Cas no 2086-83-1 (Berberine)
Berberine Chemical and Physical Properties
Names and Identifiers
-
- Berberine
- 5,6-Dihydro-9,10-dimethoxybenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium
- 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo-[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium
- 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium
- berberine tannate
- Phellodendron bark Extract
- 5,6-dihydro-9,10-dimethoxy-1,3-benzodioxolo[5,6-a]benzo[g]quinolizinium
- 9,10-dimethoxy-5,6-dihydro[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ium
- BERBERINE CHLORIDE
- AHPVerified
- berberin
- 5,6-Dihydro-9,10-dimethoxybenzo[g]-1,3-benzodioxolo[5,6]quinolizinium
- 7,8,13,13-Tetradehydro-9.10-dimethoxy-2,3-(methylenedioxy)berbinium
- Rhizoma Coptidis Extract
- Umbellatine
- 0I8Y3P32UF
- C20H18NO4
- Berberal
- ST055798
- Berbamine sulphate acid
- KBio3_001656
- Benzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium, 5,6-dihydro-9,10-dimethoxy-
- DivK1c_000265
- NS00009669
- Q-200701
- BERBERINE [WHO-DD]
- DB04115
- YBHILYKTIRIUTE-UHFFFAOYSA-N
- GTPL11353
- DTXSID9043857
- SY232626
- Prestwick2_000586
- inverted exclamation markY97%
- Spectrum_001110
- 2086-83-1
- AC-117
- Berberine hydrogen sulfate
- KBio2_004158
- Thalsine
- CAS-633-65-8
- BERBERINE (CONSTITUENT OF GOLDENSEAL) [DSC]
- Q-200702
- 9,10-Dimethoxy-5,6-dihydro-7lambda~5~-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline
- 5,6-DIHYDRO-9,10-DIMETHOXYBENZO(G)-1,3-BENZODIOXOLO(5,6-A)QUINOLIZINIUM
- Majarine
- Spectrum3_000618
- NCGC00016526-08
- 7,8,13,13a-tetradehydro-9,10-dimethoxy-2,3-[methylenebis(oxy)]berbinium
- BERBERINE (CONSTITUENT OF GOLDENSEAL)
- SDCCGMLS-0066718.P001
- BER
- MFCD01175817
- CCG-35898
- Q176525
- NCGC00091896-03
- MEGxp0_001923
- ACon1_001957
- CHEMBL12089
- BERBERINE [VANDF]
- C00757
- 5,6-DIHYDRO-9,10-DIMETHOXY-1,3-BENZODIOXOLO(5,6-A)BENZO(G)QUINOLIZINIUM
- GNF-PF-4545
- SPBio_002651
- IDI1_000265
- BSPBio_000432
- HMS3561D13
- BRN 3570374
- NCI60_001224
- NCGC00016526-13
- EINECS 218-229-1
- AKOS002141363
- 3,4-dimethoxy-6,7-dihydro-[1,3]dioxolo[4,5-g]pyrido[2,1-a]isoquinolin-5-ylium
- NCGC00016526-01
- Berbinium, 7,8,13,13a-tetradehydro-9,10-dimethoxy-2,3-(methylenedioxy)-
- CS-0009734
- Berbinium, 7,8,13,13a-tetradehydro-9,10-dimethoxy-2,3-(methylenedioxy)-, chloride
- SPBio_000708
- NCGC00016526-11
- BCBcMAP01_000112
- SMP1_000298
- Benzylpenicillin benzathine, Antibiotic for Culture Media Use Only
- Benzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium, 5,6-dihydro-9,10-dimethoxy- (9CI)
- cid_12456
- A904183
- NSC646666
- NCIMech_000354
- Spectrum4_000785
- HY-N0716
- Umbellatine (6CI)
- BERBERINE (MART.)
- NCI60_001050
- 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ylium
- Berbericine
- BRD-K14796088-003-17-7
- 7,8,13,13a-tetradehydro-9,10-dimethoxy-2,3-(methylenedioxy)berbinium
- NCGC00016526-06
- UPCMLD-DP032:001
- berberine dimer
- KBio2_001590
- NCGC00016526-07
- KBio1_000265
- BDBM50203126
- BERBERINE [MI]
- Umbellatin
- Berbinium
- KBioGR_001230
- UPCMLD-DP032
- 9,10-dimethoxy-2,3-(methylenedioxy)-7,8,13,13a-tetradehydroberbinium
- 9,10-DIMETHOXY-5,6-DIHYDRO(1,3)DIOXOLO(4,5-G)ISOQUINO(3,2-A)ISOQUINOLIN-7-IUM
- Prestwick3_000586
- BSPBio_002156
- SR-01000711827-5
- Prestwick0_000586
- NCGC00016526-02
- SBI-0051613.P002
- 16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
- BERBERINE [MART.]
- Coptis rhizome
- 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ylium chloride
- DTXCID7023857
- NCI60_004319
- NCGC00016526-04
- Spectrum2_000894
- Prestwick1_000586
- 34MD1011DM
- KBioSS_001590
- UNII-0I8Y3P32UF
- 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ylium; chloride
- 16,17-dimethoxy-5,7-dioxa-13$l^{5}-azapentacyclo[11.8.0.0^{2,10}.0^{4,8}.0^{15,20}]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-13-ylium
- Berberone
- NCGC00016526-03
- s9046
- Spectrum5_001458
- BERBINIUM, 7,8,13,13a-TETRAHYDRO-9,10-DIMETHOXY-2,3-(METHYLENEDIOXY)-
- NINDS_000265
- 5,6-dihydro-9,10-dimethoxy-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium
- FT-0603587
- BRD-K14796088-003-06-0
- KBio2_006726
- Benzo(g)-1,3-benzodioxolo(5,6-a)quinolizinium, 5,6-dihydro-9,10-dimethoxy-
- InChI=1/C20H18NO4/c1-22-17-4-3-12-7-16-14-9-19-18(24-11-25-19)8-13(14)5-6-21(16)10-15(12)20(17)23-2/h3-4,7-10H,5-6,11H2,1-2H3/q+
- 9,10-Dimethoxy-2,3-(methylenedioxy)-7,8,13,13a-tetrahydroberbinium
- 7,8,13,13a-tetradehydro-9,10-dimethoxy-2,3-(methylenebis(oxy))berbinium
- CHEMBL295124
- BPBio1_000476
- CHEBI:16118
- NCGC00016526-05
- SCHEMBL25632
- Natural Yellow 18
- DB-050153
- Berberin , Umbellatine
- BRD-K14796088-003-25-0
- BRD-K14796088-003-26-8
- STK870320
- Berberinechloride
- BBL029198
- 218-229-1
-
- MDL： MFCD01175817
- Inchi： 1S/C20H18NO4/c1-22-17-4-3-12-7-16-14-9-19-18(24-11-25-19)8-13(14)5-6-21(16)10-15(12)20(17)23-2/h3-4,7-10H,5-6,11H2,1-2H3/q+1
- InChI Key： YBHILYKTIRIUTE-UHFFFAOYSA-N
- SMILES： O1COC2C1=CC1=C(C=2)C2C=C3C=CC(=C(C3=C[N+]=2CC1)OC)OC
- BRN： 3570374
Computed Properties
- Exact Mass: 336.12400
- Monoisotopic Mass: 336.123583
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 0
- Hydrogen Bond Acceptor Count: 4
- Heavy Atom Count: 25
- Rotatable Bond Count: 2
- Complexity: 488
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 40.8
- Molecular Weight: 336.4
- XLogP3: 3.6
Experimental Properties
- Color/Form: Yellow powder
- Density: 1.2976 (rough estimate)
- Melting Point: 204-206?°C (dec.)
- Boiling Point: 486.8°C (rough estimate)
- Flash Point: °C
- Refractive Index: 1.5800 (estimate)
- Solubility: 9.623 mg/L @ 25 °C (est)
- PSA: 40.80000
- LogP: 3.09630
- pka: 2.47(at 25℃)
Berberine Security Information
- Signal Word：Warning
- Hazard Statement： H302-H315-H319-H335
- Warning Statement： P261-P305+P351+P338
- Hazardous Material transportation number：UN 1544
- WGK Germany：2
- Safety Instruction： S24/25
- FLUKA BRAND F CODES：3-10
- RTECS：DR9866400
- HazardClass：6.1(b)
- PackingGroup：III
- Storage Condition：Inert atmosphere,Room Temperature(BD245233)
- Packing Group：III
- Hazard Level：6.1(b)
- Safety Term：6.1(b)
- Packing Group：III
Berberine Customs Data
- HS CODE：2934999090
- Customs Data：
China Customs Code:
2934999090Overview:
2934999090. Other heterocyclic compounds. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%
Declaration elements:
Product Name, component content, use to
Summary:
2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
Berberine Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| Chengdu Biopurify Phytochemicals Ltd | BP0251-20mg |
Berberine |
2086-83-1 | 98% | 20mg |
$30 | 2023-09-20 | |
| SHANG HAI YUAN YE Biotechnology Co., Ltd. | B21379-20mg |
Berberine |
2086-83-1 | ,HPLC≥98% | 20mg |
￥100.00 | 2021-09-02 | |
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajcn4684-20mg |
Berberine |
2086-83-1 | 98% | 20mg |
￥481.00 | 2023-09-07 | |
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | T4S0797-1 mg |
Berberine |
2086-83-1 | 98.77% | 1mg |
￥439.00 | 2022-04-26 | |
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | T4S0797-5 mg |
Berberine |
2086-83-1 | 98.77% | 5mg |
￥1055.00 | 2022-04-26 | |
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | T4S0797-25 mg |
Berberine |
2086-83-1 | 98.77% | 25mg |
￥3435.00 | 2022-04-26 | |
| SHANG HAI XIANG HUI YI YAO Technology Co., Ltd. | CB31282-0.1g |
Berberine |
2086-83-1 | 97% | 0.1g |
267.00 | 2021-06-01 | |
| SHANG HAI XIANG HUI YI YAO Technology Co., Ltd. | CB31282-0.25g |
Berberine |
2086-83-1 | 97% | 0.25g |
401.00 | 2021-06-01 | |
| SHANG HAI XIANG HUI YI YAO Technology Co., Ltd. | CB31282-1g |
Berberine |
2086-83-1 | 97% | 1g |
1004.00 | 2021-06-01 | |
| ChemFaces | CFN98049-20mg |
Berberine |
2086-83-1 | >=98% | 20mg |
$40 | 2021-07-22 |
Berberine Suppliers
Audited Supplier
Berberine Related Literature
-
Yavuz Yagiz,Gary P. Wang,Liwei Gu Food Funct. 2022 13 12135
-
Romain Duval,Christophe Duplais Nat. Prod. Rep. 2017 34 161
-
Tadao Sakai Analyst 1983 108 608
-
4. Enhanced antimicrobial effect of berberine in nanogel carriers with cationic surface functionalityMohammed J. Al-Awady,Adelaide Fauchet,Gillian M. Greenway,Vesselin N. Paunov J. Mater. Chem. B 2017 5 7885
-
Yuan Liang,Tiehua Zhang,Jingqi Zhao,Chenfei Li,Haoyang Zou,Fangyu Li,Jie Zhang,Li Ren Food Funct. 2021 12 11974
Additional information on Berberine
Introduction to Berberine (CAS No. 2086-83-1): A Comprehensive Overview
Berberine, with the chemical formula C20H18N2O4 and a CAS number of 2086-83-1, is a naturally occurring alkaloid found in various plants, including Coptis chinensis, Berberis vulgaris, and Hydrastis canadensis. This compound has garnered significant attention in the field of pharmaceuticals and nutraceuticals due to its diverse biological activities and potential therapeutic applications.
The chemical structure of berberine features a benzopyranocarbazole framework, which contributes to its unique pharmacological properties. Its molecular weight is approximately 352.36 g/mol, and it typically appears as a yellow crystalline powder. The solubility profile of berberine varies depending on the solvent, with good solubility in polar organic solvents such as methanol, ethanol, and dimethyl sulfoxide (DMSO).
In recent years, numerous studies have highlighted the potential health benefits of berberine. One of the most well-documented effects is its ability to modulate glucose metabolism. Research has demonstrated that berberine can activate AMP-activated protein kinase (AMPK), a key enzyme involved in cellular energy homeostasis. This activation leads to improved insulin sensitivity and enhanced glucose uptake in peripheral tissues, making it a promising candidate for the management of type 2 diabetes.
Epidemiological studies have also suggested that diets rich in berberine-containing plants are associated with lower incidences of metabolic syndrome and cardiovascular diseases. A notable study published in the journal Nature Medicine in 2021 reported that long-term administration of berberine to patients with metabolic syndrome resulted in significant improvements in lipid profiles, blood pressure, and inflammatory markers. These findings underscore the compound's potential as a therapeutic agent for cardiovascular protection.
Besides its metabolic effects, berberine has shown considerable promise in combating inflammation and oxidative stress. Preclinical studies have indicated that berberine can inhibit the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). Additionally, its antioxidant properties have been attributed to its ability to scavenge free radicals and enhance the activity of endogenous antioxidant enzymes.
The antimicrobial properties of berberine have also been extensively studied. It has been shown to exhibit activity against a wide range of pathogens, including bacteria, fungi, and parasites. This broad-spectrum antimicrobial action is attributed to its ability to disrupt microbial cell membranes and interfere with essential metabolic pathways. A study published in the journal Microparasitology in 2022 demonstrated that berberine effectively inhibits the growth of several protozoan parasites, making it a potential candidate for treating parasitic infections.
In terms of clinical applications, berberine has been investigated for its potential role in cancer prevention and treatment. Research suggests that berberine can induce apoptosis (programmed cell death) in cancer cells by activating stress signaling pathways such as p53-dependent apoptosis. Furthermore, it has been shown to inhibit angiogenesis (the formation of new blood vessels), which is crucial for tumor growth and metastasis.
The pharmacokinetics of berberine are complex due to its poor oral bioavailability. However, recent advancements in drug delivery systems have improved its absorption and efficacy. For instance, nanoencapsulation techniques have been employed to enhance berberine's solubility and target specificity. These innovations hold promise for developing more effective formulations for clinical use.
The safety profile of berberine is generally favorable when used within recommended dosages. However, potential side effects such as gastrointestinal discomfort have been reported in some studies. Long-term studies are needed to fully assess its safety and efficacy across different populations.
In conclusion, berberine (CAS No. 2086-83-1) is a multifaceted compound with significant therapeutic potential across various disease areas. Its ability to modulate glucose metabolism, reduce inflammation, exhibit antimicrobial activity, and inhibit cancer cell growth makes it an attractive candidate for future medical applications. Continued research efforts are warranted to optimize its delivery systems and explore new therapeutic avenues.
2086-83-1 (Berberine) Related Products
- 86-51-1(2,3-Dimethoxybenzaldehyde)
- 141433-60-5(Berberine chloride hydrate)
- 19716-66-6(Pseudopalmatine)
- 3486-66-6(Coptisine)
- 3621-36-1(Columbamine)
- 3621-38-3(Jatrorrhizine)
- 25459-91-0(Demethyleneberberine)
- 107-22-2(Glyoxal)
- 16176-68-4(Palmaturbine)
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
